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AbstrACt
Objective The study aimed to evaluate the impact of 
a multidisciplinary inpatient heart failure team (HFT) on 
treatment, hospital readmissions and mortality of patients 
with decompensated heart failure (HF).
Methods A retrospective service evaluation was 
undertaken in a UK tertiary centre university hospital 
comparing 196 patients admitted with HF in the 6 months 
prior to the introduction of the HFT (pre-HFT) with all 
211 patients seen by the HFT (post-HFT) during its first 
operational year.
Results There were no significant differences in patient 
baseline characteristics between the groups. Inpatient 
mortality (22% pre-HFT vs 6% post-HFT; p<0.0001) 
and 1-year mortality (43% pre-HFT vs 27% post-HFT; 
p=0.001) were significantly lower in the post-HFT cohort. 
Post-HFT patients were significantly more likely to be 
discharged on loop diuretics (84% vs 98%; p=<0.0001), 
ACE inhibitors (65% vs 76%; p=0.02), ACE inhibitors and/
or angiotensin receptor blockers (83% vs 91%; p=0.02), 
and mineralocorticoid receptor antagonists (44% vs 68%; 
p<0.0001) pre-HFT versus post-HFT, respectively. There 
was no difference in discharge prescription rates of beta-
blockers (59% pre-HFT vs 63% post-HFT; p=0.45). The 
mean length of stay (17±19 days pre-HFT vs 19±18 
days post-HFT; p=0.06), 1-year all-cause readmission 
rates (46% pre-HFT vs 47% post-HFT; p=0.82) and 
HF readmission rates (28% pre-HFT vs 20% post-HFT; 
p=0.09) were not different between the groups.
Conclusions The introduction of a specialist inpatient HFT 
was associated with improved patient outcome. Inpatient 
and 1-year mortality were significantly reduced. Improved 
use of evidence-based drug therapies, more intensive 
diuretic use and multidisciplinary care may contribute to 
these differences in outcome.
IntroduCtIon
Despite major advances in medical and 
device therapy, the prognosis of patients 
hospitalised with heart failure (HF) remains 
poor. In the latest UK National Heart Failure 
Audit (2013/2014), 9.5% of such patients 
died during their hospital stay. For those who 
survived to discharge, the 5-year mortality for 
patients admitted between 2009 and 2014 
was 45.5%, with a median follow-up period 
Heart failure and cardiomyopathies
Key messAges
What is already known about this subject?
 ► Patients hospitalised with heart failure represent 
a large and growing healthcare burden. These 
patients have a poor prognosis with very high 
inpatient and early postdischarge mortality. 
Outpatient specialist multidisciplinary care 
improves outcome for these patients. However, 
very little is known regarding the impact 
of specialist teams treating inpatients with 
decompensated heart failure.
What does this study add?
 ► Introduction of a multidisciplinary team targeting 
inpatients with decompensated heart failure was 
associated with significant reductions in inpatient 
and 1-year mortality.
How might this impact on clinical practice?
 ► Recent UK National Institute for Health and 
Care Excellence guidelines for acute heart 
failure recommend early and continuing input 
of a specialist heart failure team for all patients 
admitted to hospital with heart failure. Our work 
strongly supports these guidelines as outcomes 
were significantly improved in patients managed 
by the multidisciplinary heart failure team. 
Hospitals admitting patients with heart failure who 
do not have a dedicated multidisciplinary heart 
failure team should consider introducing one.
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of only 473 days.1 Patients who were not managed and 
followed up by cardiologists were significantly more likely 
to die than those who were, even after adjustment for 
confounders.1 The financial burden is also significant, 
with HF estimated to account for 2% of the total National 
Health Service (NHS) expenditure and 5% of all emer-
gency hospital admissions in the UK.2 Furthermore, HF 
admissions are projected to increase by 50% over the 
next 25 years, mainly due to an ageing population.3 4
HF is a complex syndrome and causes multisystem 
morbidity, psychological ill-health and social prob-
lems. Because HF is predominantly a disease affecting 
older people, there are also frequently adverse inter-
actions between HF and pre-existing comorbidities. 
Consequently, the management of HF needs to be 
multifaceted to reflect this. The importance of specialist 
multidisciplinary care for patients with HF is reflected 
in national and international guidelines and is strongly 
recommended by National Institute for Health and Care 
Excellence, the European Society of Cardiology (1A 
recommendation) and the American Heart Association/
American Stroke Association (1B recommendation).2 5 6 
Multidisciplinary care in the outpatient setting improves 
patient well-being, reduces hospital admissions and 
improves outcome.7 8 There are, however, few data avail-
able on the impact of specialist teams treating inpatients 
with decompensated HF. We now report on the impact 
of introducing a specialist heart failure team (HFT) in 
a university hospital in the UK. The team was launched 
on a background of a poor performance in a National 
Health Care Commission Audit of Heart Failure Manage-
ment. The aim of the HFT was to provide equal access to 
specialist care wherever the patient presented within the 
hospital.
methods
This is a single-centre, retrospective, service evaluation 
performed at University Hospital Southampton NHS 
Trust, UK, after an HFT was established. The team 
comprised two specialist HF nurses, a part-time phar-
macist and a clinical fellow, and was led by a consultant 
cardiologist with a specialist interest in HF. The HFT 
reviewed and optimised the care of all patients referred 
with a primary admitting diagnosis of HF regardless of 
patients' location in the hospital or the speciality of the 
responsible team. There were no specific referral criteria, 
but we encouraged referral of all patients with a primary 
diagnosis of HF. HFT input included medication manage-
ment, regular reviews throughout admission and early 
outpatient follow-up (<2 weeks postdischarge) where 
appropriate. Selected appropriate patients were consid-
ered for transfer to a cardiology bed for more intensive 
treatment.
A detailed, systematic, unblinded case note review was 
conducted on all patients seen by the HFT during its 
first year of operation (post-HFT) and all patients hospi-
talised with a primary diagnosis of HF in the 6 months 
immediately prior to the HFT commencing work (pre-
HFT). A 6-month period was used to include a similar 
number of patients preintroduction and postintroduc-
tion of the HFT.
The data collected included medications on admis-
sion and on discharge, length of hospital stay, therapies 
received, inpatient deaths, follow-up plans and readmis-
sions. One-year mortality was determined from the case 
notes, hospital computer records and by phoning the 
general practitioner surgery if required. Comparisons 
were then made between the pre-HFT and post-HFT 
groups. Formal ethical approval was not required; 
however, the study was registered with the Trust’s Clinical 
Effectiveness Department.
stAtIstICAl AnAlysIs
IBM SPSS Statistics (version 20.0) software was used for 
all statistical analyses. Data are presented as mean±SD, 
except where stated. For continuous variables Shap-
iro-Wilk analyses checked normality of the underlying 
distribution. Having determined that non-parametric 
tests were required, the two groups were compared using 
the Mann-Whitney U test. The 2 test was used for compar-
ison of binomial data. Significance was determined if 
two-sided p values were <0.05. Kaplan-Meier curves were 
derived to compare mortality between the groups.
In-patient data were complete for both cohorts. 
Follow-up data were complete in terms of mortality in the 
post-HFT cohort but was incomplete on three patients in 
the pre-HFT cohort. These three patients were consid-
ered to be alive and not readmitted to hospital for the 
sake of analysis.
results
Patient population
During its first year of operation, the HFT reviewed 
211 patients (post-HFT) with a mean age of 72.0±13.3 
years. In the preceding 6 months, 215 patients were 
coded as having a primary diagnosis of HF; case note 
review confirmed that 196 patients had been correctly 
coded. The mean age of these 196 patients (pre-HFT) 
was 74.0±13.2 years. This trend towards slightly younger 
patients in the post-HFT group did not reach statistical 
significance (p=0.08). The baseline characteristics of the 
two cohorts are detailed in table 1.
There were no significant differences in important 
clinical characteristics between the two cohorts; there 
were similar proportions of patients with a history of isch-
aemic heart disease, atrial fibrillation, hypertension and 
diabetes and of female patients. Renal function, serum 
sodium, heart rate and systolic blood pressure on admis-
sion were also similar between the two groups. There 
was a non-significant trend towards slightly younger 
patients with more severe LV dysfunction in the post-HFT 
cohort. Echocardiography was performed during the 
index admission in 82% of the pre-HFT and 79% of the 
post-HFT (p=0.47) groups.
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Table 1 Baseline characteristics
Pre-HFT Post-HFT p Value
Age 74.0±13.2 years 72.0±13.3 years 0.08
Female gender 70 (36%) 85 (40%) 0.34
IHD 103 (51%) 107 (53%) 0.67
Prior MI 72 (35%) 69 (34%) 0.82
Diabetes 54 (28%) 55 (26%) 0.74
Heart rate 87±21 bpm 89±26 bpm 0.77
Systolic BP 126±28 mmHg 126±25 mmHg 0.62
AF 84 (43%) 102 (48%) 0.27
QRS duration 117±37 ms 116±44 ms 0.50
Moderate/severe LVSD 137 (70%) 165 (78%) 0.06
Preserved LV 31 (15%) 30 (14%) 0.5
Sodium 135±6 mmoL/L 135±6 mmoL/L 0.53
Urea 12±8 mmoL/L 12±12 mmoL/L 0.11
eGFR 48±23 mL/min/1.73 m2 51±22 mL/min/1.73 m2 0.27
Haemoglobin 122±22 g/L 124±23 0.42
 AF, atrial fibrillation/flutter; BP, blood pressure; bpm, beats per minute; eGFR, estimated glomerular filtration rate; HFT, heart failure team; 
IHD, ischaemic heart disease; LV, left ventricle; LVSD, left ventricular systolic dysfunction; MI, myocardial infarction.
Figure 1 Kaplan-Meier curve showing survival after admission to hospital in the pre-HFT and post-HFT cohorts. Survival was 
significantly higher in the post-HFT cohort. HFT, heart failure team.
mortality
Inpatient and 1-year mortality were significantly reduced in 
the post-HFT cohort. In the pre-HFT group, 44 out of 196 
patients died as an inpatient (22% inpatient mortality), 
whereas 13 out of 211 patients in the post-HFT group died 
(6% inpatient mortality) (p<0.0001). At 1-year postadmis-
sion, 84 out of 196 patients (43%) had died in the pre-HFT 
cohort, whereas 57 out of 211 patients (27%) had died in 
the post-HFT cohort (p=0.001) (figures 1 and 2).
Pharmacotherapy
On admission there were no differences in the prescrip-
tion rates of ACE inhibitors (ACE-I), angiotensin receptor 
blockers (ARB), ACE-I and/or ARB, beta-blockers, 
mineralocorticoid receptor antagonists (MRAs) or loop 
diuretics between the pre-HFT and post-HFT groups, 
respectively (table 2). There was a significantly higher 
proportion of patients taking thiazides on admission in 
the post-HFT group.
On discharge, the prescription rates of both medications 
with known prognostic benefit (ACE-I, ACE-I and/or ARB, 
and MRA) and medications with a symptomatic benefit 
(loop and thiazide diuretics) were significantly higher in 
patients in the post-HFT cohort (table 3). During their 
hospital stay, post-HFT patients were more likely to receive 
intravenous loop diuretics, more likely to be discharged 
 on 25 S
eptem
ber 2018 by guest. P
rotected by copyright.
http://openheart.bm
j.com
/
O
pen H
eart: first published as 10.1136/openhrt-2016-000547 on 8 M
arch 2017. D
ow
nloaded from
 
Open Heart
4 Masters J, et al. Open Heart 2017;4:e000547. doi:10.1136/openhrt-2016-000547
Figure 2 Mortality, 1-year all-cause and HF readmission and specialist follow-up rates in the pre-HFT and post-HFT cohorts. 
*Denotes statistically significant difference between pre-HFT and post-HFT. HFT, heart failure team.
Table 2 Admission medications
Medication Pre-HFT Post-HFT p Value
Loop diuretic 60% 62% 0.59
ACE inhibitor 48% 46% 0.8
ARB 15% 15% 0.95
ACE-I and/or ARB 62% 61% 0.82
Beta-blocker 37% 40% 0.56
MRA 19% 23% 0.35
Thiazide 5% 11% 0.01
ARB, angiotensin receptor blockers; HFT, heart failure team; MRA, 
mineralocorticoid receptor antagonists.
Table 3 Discharge medications
Medication Pre-HFT Post-HFT p Value
Loop diuretic 85% 98% <0.0001
ACE inhibitor 65% 76% 0.02
ARB 18% 16% 0.67
ACE-I and/or ARB 83% 91% 0.02
Beta-blocker 59% 63% 0.45
MRA 44% 68% <0.0001
Thiazide 5% 17% 0.001
ARB, angiotensin receptor blockers; HFT, heart failure team; MRA, 
mineralocorticoid receptor antagonists.
on a diuretic and were discharged on higher doses of 
loop diuretic. Intravenous loop diuretic was used in 76% 
of pre-HFT versus 88% of post-HFT patients (p<0.002). 
Eighty-four per cent of the pre-HFT patients were 
discharged on a loop diuretic (70% furosemide and 14% 
bumetanide) compared with 98% of post-HFT patients 
(54% furosemide and 45% bumetanide) (p<0.0001).
Post-HFT patients received higher doses of oral 
diuretics on discharge: the mean bumetanide equivalent 
dose (bumetanide 1 mg = furosemide 40 mg) was 2.4 mg 
in the post-HFT cohort versus 1.6 mg in the pre-HFT 
cohort (p<0.001). Discharge prescription rates of thia-
zide diuretics were also more frequent in the post-HFT 
patients: 5% pre-HFT versus 17% post-HFT (p<0.001).
Advanced hF therapies
No significant differences in the use of advanced thera-
pies were observed between the pre-HFT and post-HFT 
cohorts. This includes the use of intravenous inotropes 
(22% vs 19%; p=0.39), intra-aortic balloon pump (5% 
vs 2%; p=0.15) and cardiac resynchronisation therapy 
(0.5% vs 2%; p=0.12) pre-HFT and post-HFT, respectively. 
Furthermore there were no significant differences in the 
number of patients receiving ventilatory support, including 
both non-invasive ventilation (16% vs 13%; p=0.4) and 
intubation and ventilation on intensive care (14% vs 8%; 
p=0.06), pre-HFT and post-HFT, respectively.
length of stay, readmissions and specialist follow-up
The mean length of stay was similar at 17±19 days pre-HFT 
and 19±18 days post-HFT (p=0.06) (figure 2). Of those 
patients successfully discharged from hospital in the 
pre-HFT cohort, 67 out of 145 patients (46%) were read-
mitted to the hospital as an emergency in the subsequent 
year, whereas 93 out of 196 (47%) were admitted from 
the post-HFT cohort (p=0.82). Of the pre-HFT readmis-
sions, 40 out of 144 (28%) were due to HF compared 
with 39 out of 196 (20%) of the post-HFT readmissions 
(p=0.09).
Of the pre-HFT cohort, 43% had specialist follow-up 
(defined as cardiology, HFT or primary care HF specialist 
nurse follow-up), whereas 81% had specialist follow-up in 
the post-HFT group (p<0.0001).
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dIsCussIon
After the introduction of an inpatient HFT, the outcome 
of patients admitted with decompensated HF was much 
better than the outcome in a very similar cohort admitted 
in the preceding 6 months. Patients managed by the 
HFT had significantly lower inpatient mortality and this 
benefit was maintained at 1-year postadmission. This 
might reflect improvements in the rates of prescribing 
of evidence-based medications and the rates of specialist 
follow-up but did not appear to be due to the use of more 
advanced therapies.
HF is an important and growing socioeconomic 
problem. Although specialist multidisciplinary care 
has been shown to improve outcomes for HF patients,8 
the vast majority of published data relate to outpatient 
programmes, typically beginning at the time of patient 
discharge. Given the high inpatient and early postdis-
charge mortality in patients hospitalised with HF, it is 
surprising that there are very few data on the effective-
ness of inpatient HF teams. McDonald et al9 examined 
the impact of an HF programme in a small randomised, 
controlled study of 70 patients admitted with HF. They 
demonstrated that a combined multidisciplinary care 
programme, starting as an inpatient, eliminated 1-month 
readmissions in a population with a 20% admission rate 
in the month before study commencement. In contrast to 
our study, patients in the routine care group and those in 
the multidisciplinary HF programme were all managed 
by cardiologists. The only difference between the groups 
was the education given to the multidisciplinary group. 
Both groups received similar medical therapy, and inter-
estingly readmissions were also eliminated in the routine 
care group.
In a separate large (n=1504) US randomised study, 
a regional, multihospital quality improvement inter-
vention failed to improve the length of stay, mortality, 
readmissions or quality of life in patients admitted with 
HF.10 However, this study involved implementation of 
standardised management care pathways rather than 
providing direct specialist clinical input individualised 
for each patient.
Our findings therefore build on a limited literature and 
support direct involvement of specialist multidisciplinary 
HFTs, starting during hospital admission. Although it 
is not a randomised study, the findings are real-world 
data, and despite very similar baseline characteristics the 
outcome of the two groups was very different.
Given the observational nature of the data, it is not 
possible to establish what aspects of HFT care, if any, 
reduced patient mortality. However, it seems likely that 
specialist care is important. Currently there is no national 
standardised care pathway for patients admitted with HF 
in the UK. Some patients are managed by cardiologists (or 
other physicians) with a specialist interest and expertise 
in HF. In contrast others are admitted under cardiologists 
or physicians without such specialist expertise. Allocation 
of care to a given physician is often somewhat arbitrary 
despite evidence that outcomes are improved in patients 
managed by cardiologists.1 11 This is in stark contrast to 
the care given to patients with some other conditions 
with comparable mortality, for example, cancers where 
management by an oncologist is appropriately consid-
ered to be standard care. Specialist care is likely to be the 
reason why the post-HFT group was more likely to receive 
evidence-based drug therapy for HF, including ACE-I and 
MRAs which improve outcome in patients with severe 
HF.12 13 After the introduction of HFT, the prescribing 
rates of all prognostically important medications were 
comparable with rates achieved in the National Heart 
Failure Audit.1 In addition, post-HFT patients received 
more intensive diuretic therapy. Although these drugs 
have not been clearly shown to improve outcome, they 
are important symptomatically. Interestingly post-HFT 
patients were not more likely to receive beta-blockers 
or more advanced HF therapies. This suggests that most 
patients in whom inpatient beta-blocker therapy was 
appropriate were already receiving these drugs under 
non-specialist care. However, postdischarge initiation 
and up-titration of medications may have been more 
likely to occur with specialist follow-up. The similar rates 
of advanced and more intensive therapies may reflect 
the fact that these treatments are usually reserved for 
the most unwell patients and that these patients were 
more likely to be referred to and managed by cardiology 
before the HFT was set up. However, it is not possible to 
determine this from our data. Moreover, advanced device 
therapy is often not performed as an inpatient as most 
patients undergo a period of stabilisation and/or optimi-
sation of medical therapy and reassessment before being 
put forward for device implantation.
An interesting observation was that post-HFT patients 
received more intensive diuretic therapy. The HFT goal 
was always to relieve congestion using whatever dose 
or combination of diuretics was necessary, whereas it 
is our experience that general physicians use diuretics 
more cautiously, particularly in the setting of renal 
dysfunction. Such patients treated by HFT received 
more intravenous and higher doses of loop diuretics 
and were more likely to be treated with a combination 
of thiazide and loop diuretics. Although furosemide 
was the most frequently prescribed loop diuretic on 
discharge, a greater proportion of post-HFT patients 
received bumetanide, which has a more predictable 
bioavailability.14 Diuretic dose has been shown to 
predict mortality in HF15; however, one study suggested 
that clinical stability may be more important than base-
line diuretic dose.16 Reducing cardiac filling pressures 
in HF reduces sympathetic activation,17 and as such it is 
biologically plausible that using higher dose diuretics 
to achieve euvolaemia could improve outcome. Indeed 
freedom from congestion has been shown to predict 
survival in class IV patients.18
The multidisciplinary nature of the HFT is also likely to 
be an important factor with different healthcare profes-
sionals complimenting one another. HF nurses are at the 
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centre of the HFT and are key to many aspects of care 
previously shown to improve outcome, including educa-
tion and improved patient self-care, follow-up monitoring 
and access to specialised HF clinics.8
We did not observe a reduction in readmissions seen as 
a result of multidisciplinary team care in previous studies.8 
This difference may be a result of our HFT focusing on 
inpatient care and the first 2 weeks following discharge; 
community HFTs were available to manage HF patients 
postdischarge in both cohorts. Also relevant is the fact 
that by markedly reducing inpatient mortality in our HFT 
cohort, many sicker patients survived to discharge. In this 
context maintaining the same level of HF readmissions 
could be considered a success.
Although much ongoing HF research is focused on 
complex imaging and drug and device therapies, it is 
encouraging to note the potential impact of an inpatient 
HFT on mortality. Our absolute risk reduction in mortality 
on discharge was 16% (6% vs 22%), which is clinically very 
relevant. This was maintained at 1 year (27% vs 43%). 
Although direct comparisons are not possible landmarks, 
HF trails have shown an absolute risk reduction in mortality 
of 18% with ACE-I,12 11% with spironolactone,13 5.5% 
with bisoprolol,19 10% with Cardiac Resynchronisation 
Therapy (CRT)20 and 7% with Implantable Cardioverter 
Defibrillator (ICDs).21 It is important for policymakers to 
remember that HF is a chronic condition, and involve-
ment of multidisciplinary teams provides patient-centred 
care and also improves outcomes and patient experience. 
Furthermore, in a condition that still has an unacceptably 
high inpatient mortality, early involvement of this team 
seems to be beneficial.
lImItAtIons
These are observational data rather than a randomised 
controlled trial, and as such it is not possible to categor-
ically separate causation and association. However, we 
believe it would be difficult ethically to design a conven-
tional randomised controlled trial at this stage given the 
evidence that outcomes are improved by specialist input.1 
Also, it is difficult to randomise patients within a hospital 
to differences in the level of service. Management 
almost inevitably improves in the control group, which 
may lead to a neutral outcome. Randomising centres to 
initiate or defer the creation of such a service in a cluster 
randomised trial might be possible and preferable.22
Not all patients admitted with HF were seen by the HFT 
as onward referral was required by the admitting team. 
Given that a similar number of patients were admitted 
with HF in the 6 months before the HFT was set up, this 
suggests that the HFT saw approximately half of all admis-
sions in its first operational 12 months. Consequently we 
cannot exclude a referral bias in favour of the post-HFT 
cohort. However, the baseline characteristics suggest that 
the two populations were very similar, while accepting 
that no assessment of cognitive function was made which 
might adversely affect patient treatment and outcome. It 
is interesting to note that following successful discharge 
the subsequent mortality within the 1-year follow-up 
period was identical for both groups at 21%, which further 
supports the belief that the two patient populations were 
well matched (pre-HFT inpatient mortality 22%, 1-year 
mortality 43% vs post-HFT inpatient mortality 6%, 1-year 
mortality 27%). Thus, the impact of the HFT does appear 
to be real.
This report is predominantly focused on inpatient care; 
specialist follow-up was variable (cardiology, HFT, primary 
care HF nurse) and some patients were discharged from 
the service within a few months. Patients could have been 
hospitalised elsewhere during follow-up, but we would 
expect any underestimation in readmissions to be equally 
balanced between the two cohorts.
ConClusIons
Specialist multidisciplinary team input for patients 
hospitalised with decompensated HF is associated with 
significantly reduced inpatient and 1-year mortality. 
Improved use of evidence-based drug therapies, together 
with more intensive diuretic use, and the multidisci-
plinary nature of the team may contribute to differences 
in patient outcome.
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